This article is more than 5 years old. Information may no longer be current.
Exactech announces 510(k) clearance for total ankle offering
Click Here to Manage Email Alerts
Exactech Inc. recently announced it has received FDA 510(k) clearance to market the Vantage Total Ankle for the treatment of patients with ankle arthritis.
According to a company press release, the fixed-bearing Vantage Total Ankle is designed to conserve bone and is an easy-to-use solution that allows for stability and mobility in total ankle arthroplasty. The offering’s curved surface talar component is reportedly structured to fit the anatomy of a diseased talus and restore the joint line.
“With the introduction of the Vantage ankle, Exactech continues its precedent of innovation in the extremities market, which began with our industry-leading Equinoxe platform shoulder system,” Darin Johnson, Exactech vice president of marketing for extremities, said in the release. “The ankle market is in need of advances in total ankle technologies. We have had the pleasure of working with a world-class design team that includes surgeons who have dedicated their careers to treatment of the ankle. Together, we have developed an implant that we believe will be an improvement for patients who need a total ankle.”
Exactech plans to begin clinical evaluation of the Vantage Total Ankle during the summer and has scheduled a full-scale release in the first quarter of 2017, according to the release.
Reference: